Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Galapagos NV announces its unaudited first half-year results, which are further detailed in its H1 2019 report available on the Galapagos website, www.glpg.com.
Eurofins Scientific, a world leader in biopharmaceutical testing acquired Alphora Research Inc. to support Eurofins’ extensive drug development platform.
Eurofins Scientific, a world leader in biopharmaceutical testing acquired Amatsigroup SAS to support Eurofins’ extensive drug development platform.
sterna biologicals selected as one of a group of top-tier European biotech companies to present at the European Biotech Investor Day on August 1, 2019 in New York City
Evelo Biosciences, Inc., a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, announced that it has entered into a loan and security agreement for up to $45 million with K2 HealthVentures, a healthcare investment firm.
Gimv, Sofinnova and Gilde Healthcare announced the sale of biopharmaceutical company Breath Therapeutics.
Net sales increased 10 per cent compared to Q2 2018, corresponding to the net of acquisitions and discontinuing operations.
Delivered 31% increase in revenue, 51% increase in operating profit and 60% increase in net profit year-on-year Delivered 21% increase in revenue, with increases in operating profit and net profit compared to Q1 2019 Increased investment in pipeline to support long-term growth
The sale of Germany-based Breath comes after the company launched two late-stage trials assessing its lead product as a treatment for a disease that affects lung transplant patients.
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, provides a trading update for the six month period ended 30 June 2019.